BPIFB1 is a member of the bactericidal permeability-increasing fold-containing family, a group of innate immune proteins whose members share a structural architecture evolved to bind lipids and engage microbial targets. The protein is abundantly expressed in the nasopharyngeal epithelium, the very tissue from which nasopharyngeal carcinoma arises, which makes its behavior in this cancer particularly consequential. According to the review, BPIFB1 is markedly downregulated in nasopharyngeal carcinoma tissues, and loss of its expression is associated with poor prognosis for patients. In other words, the more the molecule disappears from tumor cells, the worse the clinical outlook tends to be, a correlation that has prompted researchers to classify it as a tumor suppressor.

What makes the story compelling from a viral oncology standpoint is the mechanism behind that loss. The review highlights accumulating evidence that BPIFB1 is directly targeted and suppressed by EBV-encoded miR-BART4, one of the microRNAs the virus produces during latent infection. Epstein–Barr virus is known to maintain its long-term residence in infected cells in part by deploying a panel of BART microRNAs, which fine-tune both viral and host gene expression without provoking strong immune detection. By steering miR-BART4 at BPIFB1, the virus appears to strip the epithelium of one of its local sentinels, a maneuver that could undermine both the tissue’s barrier functions and its capacity to coordinate immune responses.

The authors frame BPIFB1 as a multi-node tumor suppressor, a description that captures the unusual breadth of its influence. Rather than acting through a single pathway, the molecule is implicated in regulating several of the classic hallmarks of cancer simultaneously. These include immune escape, the process by which tumor cells avoid recognition and destruction by cytotoxic lymphocytes; metastatic invasion, the acquisition of motile and tissue-infiltrating behavior that allows cancer cells to spread; and glycolytic reprogramming, the metabolic shift toward heightened glucose fermentation even in the presence of oxygen, known as the Warburg effect, which supports rapid proliferation.

The reach of BPIFB1 extends further still. The review identifies roles for the molecule in modulating radioresistance, a phenomenon of particular clinical relevance in nasopharyngeal carcinoma, where radiotherapy is a mainstay of treatment and tumor cells that withstand radiation drive treatment failure. BPIFB1 also appears to influence cell proliferation directly and to engage inflammation-associated signaling, including pathways centered on NF-kappaB, a transcription factor family that sits at the hub of inflammatory responses and is frequently co-opted in malignancy. Chronic inflammation in the tumor microenvironment is widely recognized as a driver of cancer progression, and a molecule capable of tempering those signals could in principle slow multiple aspects of tumor evolution at once.

An intriguing theme running through the review is that BPIFB1 does not behave identically in every tissue. The authors describe tissue-specific functional heterogeneity across multiple tumor types, citing evidence from breast, lung and gastric cancers in addition to nasopharyngeal carcinoma. This kind of context dependence is increasingly appreciated in cancer biology: a protein that suppresses growth in one epithelium may have more nuanced or even opposing effects elsewhere, depending on the local repertoire of interacting partners, signaling pathways and metabolic conditions. For researchers hoping to translate BPIFB1 findings into the clinic, this heterogeneity is a caution as well as an opportunity, since any therapeutic strategy would need to account for how the molecule behaves in the specific tissue being treated.

To situate these functional findings mechanistically, the review systematically summarizes the molecular structure of BPIFB1 and the regulatory mechanisms underlying its aberrant expression in cancer. The protein belongs to the PLUNC subfamily, which is expressed selectively in the upper airways and is thought to participate in the mucosal defense of these surfaces, contributing to the antimicrobial and anti-inflammatory properties of airway secretions. That lineage makes evolutionary sense of the molecule’s dual character: it is simultaneously an innate immune effector shaped for mucosal surveillance and, according to the evidence assembled by the Changsha team, a regulator of intracellular signaling circuits that tumors exploit for survival and spread.

Beyond cancer, the review casts a wider net, surveying recent advances in BPIFB1-related research across multi-system diseases. This broader framing reflects a growing recognition that innate immune molecules of the airway are not narrowly specialized anti-bacterial agents but participants in systemic biology, with potential relevance wherever epithelial barriers, mucosal immunity and inflammatory signaling intersect. The disease geography of nasopharyngeal carcinoma itself underscores the point, since the tight association between EBV and this tumor in specific populations suggests that host genetic and environmental factors modulating mucosal immunity may shape risk in ways that a single-virus, single-tissue perspective would miss.

On the translational front, the authors discuss BPIFB1’s potential as both a biomarker and a therapeutic target. As a biomarker, the molecule’s consistent downregulation in nasopharyngeal carcinoma and its association with poor prognosis suggest that measuring its expression could help stratify patients or track disease behavior. As a therapeutic target, the challenge is thornier, because restoring a suppressed tumor suppressor inside malignant cells is far more difficult than inhibiting an overactive oncogene. Yet the viral connection offers a conceptual foothold: if EBV-encoded miR-BART4 is the principal driver of BPIFB1 loss, strategies aimed at blunting that microRNA or counteracting its downstream effects could, in principle, reawaken the suppressed protein. The open-access review, which was published on 25 September 2026 and supported by the Project of Changsha Natural Science Foundation, does not claim such interventions exist today; it consolidates the mechanistic groundwork that would make them conceivable.

For a cancer that remains a major burden in Southern China and Southeast Asia, and for the broader field of virus-associated malignancy, the synthesis offered by Cai and colleagues is a reminder that the tumor microenvironment is shaped as much by what the immune system loses as by what the tumor gains. BPIFB1, a molecule of the airway’s first line of defense, emerges from this review as a lens through which viral manipulation, metabolic reprogramming, inflammatory signaling and immune evasion can be seen as a single connected story. Whether future work can convert that mechanistic insight into clinical tools, from prognostic assays to microRNA-targeted therapies, will depend on validating these roles across cohorts and disease settings, but the review makes a clear case that this underappreciated epithelial protein deserves a prominent place on the research agenda for nasopharyngeal carcinoma and beyond.

Subject of Research: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1 in nasopharyngeal carcinoma

Article Title: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases

Article References: Cai, J., Jiang, F., Xiao, L., & Zhang, W. (2026). Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04580-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04580-z

Keywords: BPIFB1, LPLUNC1, nasopharyngeal carcinoma, Epstein-Barr virus, miR-BART4, tumor suppressor, immunomodulation, glycolytic reprogramming, radioresistance, NF-kappaB, innate immunity, multi-system diseases